[logo] HealthTree Foundation
search person

Navigating the ASH 2014 Myeloma Maze - Making It REAL For the Patient and Caregiver

Posted: Dec 17, 2014
Navigating the ASH 2014 Myeloma Maze - Making It REAL For the Patient and Caregiver image
link icon facebook logo X logo linkedin logo reddit logo email icon

When I was at one of the sessions that focused on the new exciting research which is being conducted on myeloma, I came to the realization that I was understanding less than 20% of what was being said. I gave the presenters 100% of my attention, and at some points I thought my head would explode. I saw people (researchers and scientists) in the room checking their cell phones, typing, and listening as well, and came to understand if much of what was being said is confusing to me, a relatively informed myeloma advocate, how is the newly diagnosed to sort through this Myeloma Maze? One way will be to listen to the Cure Panel Broadcast by Dr. Parameswaran Hari, one of my Great Eight of worldwide myeloma specialists. This will offer patients an opportunity to ask their questions to one of the very best of the best, and hear his perceptive of all of the research, clinical trials, and treatments presented at ASH. The broadcast will be at 5:00 pm EST on December 17th. For details on how to listen and ask your question CLICK HERE.

As patients, if you go to the abstracts from the ASH, I think you will get lost in this massive maze of information. Some of the best summaries by the IMF, MMRF, MyelomaCrowd, Cure Talks, and Myeloma Beacon are now available on line and provided by myeloma advocates as fellow patients themselves try to make their reports patient and caregiver friendly. All of these organizations send a number of patient advocates to attend and cover most all of the sessions. For example, my fellow Cure Panel members Jack Aiello, and Cynthia Chmielewski represented the IMF, and MyelomaCrowd had Pat Killingsworth, Lizzy Smith, Jenny Alhstrom, and myself. To read these patient friendly summaries from ASH 2014, the following sites would be my first choice for information.
Myeloma Crowd - ASH 2014 Highlights https://www.myelomacrowd.org/
MMRF - ASH 2014 Day One Roundup and Day Two Roundup Myeloma Cure Talks - ASH 2014 and many other great Myeloma BroadcastsMyeloma Beacon - ASH 2014 CoverageMyeloma Blogs of ASH - Living with Multiple Myeloma and Myeloma Survival Blog You get all of the new study data on the currently approved drugs Kyprolis and Pomalyst, as well as the yet-to-be approved new class of monoclonal antibody drugs Elotuzumab, Daratumumab, and SAR. In addition, new oral proteasome inhibitors of Oprozomib and Ixazomib offer the potential for an all oral treatment as a substitute for the current standard of RVD. The "V" is Velcade and is currently administered by IV or subcutaneous injection at the clinic. I will not go over that which has been so well covered by all of these exceptional myeloma advocates. Please take the time to visit each of the links above for a patient friendly tour though the ASH 2014 Myeloma Maze. The topic for my next blog post will be the exceptional research which looks to have a very positive result for high risk myeloma and some research which may finally lead us to a CURE for all patients, but seems to have flown under the radar.
Good luck and may God Bless your Cancer Journey. For more information on multiple myeloma survival rates and treatments and you can follow me on twitter at: https://twitter.com/grpetersen1

When I was at one of the sessions that focused on the new exciting research which is being conducted on myeloma, I came to the realization that I was understanding less than 20% of what was being said. I gave the presenters 100% of my attention, and at some points I thought my head would explode. I saw people (researchers and scientists) in the room checking their cell phones, typing, and listening as well, and came to understand if much of what was being said is confusing to me, a relatively informed myeloma advocate, how is the newly diagnosed to sort through this Myeloma Maze? One way will be to listen to the Cure Panel Broadcast by Dr. Parameswaran Hari, one of my Great Eight of worldwide myeloma specialists. This will offer patients an opportunity to ask their questions to one of the very best of the best, and hear his perceptive of all of the research, clinical trials, and treatments presented at ASH. The broadcast will be at 5:00 pm EST on December 17th. For details on how to listen and ask your question CLICK HERE.

As patients, if you go to the abstracts from the ASH, I think you will get lost in this massive maze of information. Some of the best summaries by the IMF, MMRF, MyelomaCrowd, Cure Talks, and Myeloma Beacon are now available on line and provided by myeloma advocates as fellow patients themselves try to make their reports patient and caregiver friendly. All of these organizations send a number of patient advocates to attend and cover most all of the sessions. For example, my fellow Cure Panel members Jack Aiello, and Cynthia Chmielewski represented the IMF, and MyelomaCrowd had Pat Killingsworth, Lizzy Smith, Jenny Alhstrom, and myself. To read these patient friendly summaries from ASH 2014, the following sites would be my first choice for information.
Myeloma Crowd - ASH 2014 Highlights https://www.myelomacrowd.org/
MMRF - ASH 2014 Day One Roundup and Day Two Roundup Myeloma Cure Talks - ASH 2014 and many other great Myeloma BroadcastsMyeloma Beacon - ASH 2014 CoverageMyeloma Blogs of ASH - Living with Multiple Myeloma and Myeloma Survival Blog You get all of the new study data on the currently approved drugs Kyprolis and Pomalyst, as well as the yet-to-be approved new class of monoclonal antibody drugs Elotuzumab, Daratumumab, and SAR. In addition, new oral proteasome inhibitors of Oprozomib and Ixazomib offer the potential for an all oral treatment as a substitute for the current standard of RVD. The "V" is Velcade and is currently administered by IV or subcutaneous injection at the clinic. I will not go over that which has been so well covered by all of these exceptional myeloma advocates. Please take the time to visit each of the links above for a patient friendly tour though the ASH 2014 Myeloma Maze. The topic for my next blog post will be the exceptional research which looks to have a very positive result for high risk myeloma and some research which may finally lead us to a CURE for all patients, but seems to have flown under the radar.
Good luck and may God Bless your Cancer Journey. For more information on multiple myeloma survival rates and treatments and you can follow me on twitter at: https://twitter.com/grpetersen1
The author Gary Petersen

about the author
Gary Petersen

Gary is a myeloma survivor and patient advocate. His work centers around helping patients live longer by helping them to find facilities who are beating the average survival statistics. You can find Gary's site at www.myelomasurvival.com and follow him on Twitter at @grpetersen1

More on Treatment Advances

New GenoPredicta Test Brings More Accurate Diagnosis and Treatment Options for Multiple Myeloma image
New GenoPredicta Test Brings More Accurate Diagnosis and Treatment Options for Multiple Myeloma
European Union Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma image
European Union Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma
Stem Cell Mobilization Options for Myeloma Patients: What’s Available and What’s Coming image
Stem Cell Mobilization Options for Myeloma Patients: What’s Available and What’s Coming
Blenrep's Return in the UK: Why it Matters for All Myeloma Patients image
Blenrep's Return in the UK: Why it Matters for All Myeloma Patients
Beyond Standard Therapy: Novel Drug Classes Showing Promise for Relapsed Myeloma image
Beyond Standard Therapy: Novel Drug Classes Showing Promise for Relapsed Myeloma
Biosimilar FDA-Approved for Myeloma Bone Strengthener Denosumab image
Biosimilar FDA-Approved for Myeloma Bone Strengthener Denosumab
See More Treatment Advances
Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.

Education

News Articles Patient Guides My Journal University Expert Webinars Find a Specialist HealthTree Podcast

Community

Connect Coach Moves All Events Community Support Groups Black Myeloma Health Resources in Spanish

Cure Hub

HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Treatment Options Twin Machine Clinical Trial Finder

Get Involved

Join a Regional Cure Team Create a fundraiser Tribute Donate Patient Surveys & Studies Connect Medical Records All Publications HealthTree Research Initiative

About us

Our Story HealthTree in The News Annual Reports

Need Help?

Contact Us FAQ & Help Center 1-800-709-1113

Legal Info

Terms of Use Privacy Policy

Follow Us

facebook instagram linkedin tiktok youtube
Download our App
Download iOS App Download Android App

Charity Navigator https://www.guidestar.org/profile/45-5354811

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2025 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811